Explain that a randomized international trial found that zoledronic acid prevented new vertebral fractures in men with osteoporosis compared with placebo.
Note that these findings mirrored the drug's effect in women, and low testosterone was not found to be a contributing factor.Intravenous zoledronic acid (Reclast) lowered the risk of vertebral fracture among men with osteoporosis, a randomized trial determined.
Compared with placebo, the bone drug cut the risk of new radiographically-detected vertebral fractures by 67% over 24 months, to 1.6% versus 4.9%, Steven Boonen, MD, PhD, of University Hospitals Leuven, Belgium, and colleagues found.
Along with this significant benefit came a reduced rate of moderate-to-severe fractures and less height loss, although there was no reduction in mortality risk, the group reported in the Nov. 1 issue of the New England Journal of Medicine.
The findings largely mirror results for osteoporotic postmenopausal women, as the researchers had noted when they first presented the findings at the American Society for Bone and Mineral Research meeting last year.
Prior studies had shown better bone mineral density among osteoporotic men taking the drug but they had looked only at surrogate markers.
02/11/2012 : By Crystal Phend / MedPage Today.
0 comments:
Post a Comment